Our Vaccines business is one of the largest in the world, developing, producing and distributing over 1.9 million vaccines every day to people across more than 150 countries.

The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta (US) site dedicated to smallpox vaccine production since 1882. Today, our vaccines continue to tackle some of the world’s most devastating diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Our pipeline of potential new vaccines covers many of the diseases still having a serious impact around the world, including malaria, HIV, TB and Ebola.

Our acquisition of Novartis' Vaccines business (excluding influenza vaccines) in early 2015 significantly expanded the number of vaccines we produce (now around 39), as well as the number of new vaccines we have in development (15), giving us the broadest portfolio of any vaccines company in the world.